Royal Sense Ltd
Incorporated in 2023, Royal Sense Ltd specializes in medical device and pharmaceutical trading.[1]
- Market Cap ₹ 62.1 Cr.
- Current Price ₹ 116
- High / Low ₹ 310 / 102
- Stock P/E 20.6
- Book Value ₹ 62.0
- Dividend Yield 0.00 %
- ROCE 13.9 %
- ROE 10.4 %
- Face Value ₹ 10.0
Pros
Cons
- Though the company is reporting repeated profits, it is not paying out dividend
- Company has a low return on equity of 11.3% over last 3 years.
- Debtor days have increased from 119 to 149 days.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Half Yearly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
| Sep 2023 6m | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|
| 8.03 | 18.96 | 27.64 | 37.75 | |
| 7.09 | 16.59 | 23.39 | 32.93 | |
| Operating Profit | 0.94 | 2.37 | 4.25 | 4.82 |
| OPM % | 11.71% | 12.50% | 15.38% | 12.77% |
| 0.01 | 0.03 | 0.08 | 0.09 | |
| Interest | 0.00 | 0.09 | 0.18 | 0.80 |
| Depreciation | 0.00 | 0.01 | 0.02 | 0.05 |
| Profit before tax | 0.95 | 2.30 | 4.13 | 4.06 |
| Tax % | 26.32% | 26.09% | 26.15% | 25.62% |
| 0.70 | 1.70 | 3.04 | 3.01 | |
| EPS in Rs | 2.03 | 3.47 | 6.12 | 5.63 |
| Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | 37% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | -1% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | -51% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 11% |
| Last Year: | 10% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
| Sep 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|
| Equity Capital | 4.90 | 4.97 | 5.35 | |
| Reserves | 13.44 | 19.60 | 27.83 | |
| 1.60 | 3.26 | 8.98 | ||
| 0.94 | 3.02 | 3.95 | ||
| Total Liabilities | 20.88 | 30.85 | 46.11 | |
| 0.05 | 1.65 | 1.82 | ||
| CWIP | 0.00 | 0.00 | 0.00 | |
| Investments | 0.43 | 0.44 | 4.43 | |
| 20.40 | 28.76 | 39.86 | ||
| Total Assets | 20.88 | 30.85 | 46.11 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
| Sep 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|
| -0.79 | 1.80 | |||
| -4.55 | -11.07 | |||
| 13.10 | 2.89 | |||
| Net Cash Flow | 7.77 | -6.39 | ||
| Free Cash Flow | -0.82 | 0.18 | ||
| CFO/OP | -33% | 58% |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
| Sep 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|
| Debtor Days | 90.48 | 117.79 | 149.29 | |
| Inventory Days | 6.27 | 53.66 | 106.73 | |
| Days Payable | 0.46 | 22.43 | 2.95 | |
| Cash Conversion Cycle | 96.29 | 149.02 | 253.07 | |
| Working Capital Days | 118.78 | 100.63 | 142.13 | |
| ROCE % | 18.04% | 13.89% |
Insights
In beta| Mar 2024 | Mar 2025 | |
|---|---|---|
| Geographic Presence (Number of States/Regions) Number |
|
|
| Net Capital Turnover Ratio Ratio |
||
| Number of Permanent Employees Number |
||
| US FDA Approved Products Number |
||
| E-Commerce Distribution Partnerships (Zepto/Blinkit) Number |
||
| Number of New Products Launched (Annual) Number |
||
Extracted by Screener AI
Documents
Announcements
-
Financial Results For The Year Ended 31St March, 2026
25 May - Board approved audited standalone and consolidated FY26 results, ESOP revision, committees, and director remuneration on 25 May 2026.
-
Board Meeting Outcome for Disclosures Pursuant To The Provisions Of Regulation 30 Of SEBI (Listing Obligation & Disclosure Requirements) Regulation, 2015 Read With Para-A Part-A Of Schedule III_ Submission Of The Outcome Of Board Meeting Of The Company.
25 May - Board approved audited FY26 standalone/consolidated results, ESOP term revision, committees, and director remuneration on 25 May 2026.
-
Non-Applicability Of The Submission Of Annual Secretarial Compliance Report Under Regulation 24A(2) Of SEBI (LODR) Regulation, 2015.
22 May - Royal Sense says FY26 Annual Secretarial Compliance Report is not applicable under SME exemption.
-
Board Meeting Intimation for Intimation Of The Board Meeting Pursuant To The Regulation 29 Of SEBI (Listing Obligation & Disclosure Requirements) Regulation, 2015.
20 May - Board meets 25 May 2026 to approve FY26 audited results and revise ESOP 2024.
-
Disclosure Under Regulation 30 Of The SEBI (LODR) Regulations, 2015.
20 May - Royal Sense launched seven pharma products and one blood pressure monitor on 20 May 2026.
Business Overview:[1][2]
RSL deals in Advanced medical devices, pharmaceuticals, diagnostics, and offers surgical solutions. It provides hospitals, laboratories, clinics, and institutions
with products like surgical accessories, instruments, equipment, consumables,
reagents, diagnostic kits, and disposable
medical supplies